Advertisement

Supportive Care in Cancer

, Volume 25, Issue 11, pp 3537–3544 | Cite as

Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials

  • Jennifer Le-Rademacher
  • Rahul Kanwar
  • Drew Seisler
  • Deirdre R. Pachman
  • Rui Qin
  • Alexej Abyzov
  • Kathryn J. Ruddy
  • Michaela S. Banck
  • Ellen M. Lavoie Smith
  • Susan G. Dorsey
  • Neil K. Aaronson
  • Jeff Sloan
  • Charles L. Loprinzi
  • Andreas S. Beutler
Original Article

Abstract

Purpose

Clinical practice guidelines on chemotherapy-induced peripheral neuropathy (CIPN) use the NCI Common Terminology Criteria for Adverse Events (CTCAE), while recent clinical trials employ a potentially superior measure, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (QLQ-CIPN20), a patient-reported outcome (PRO). Practitioners and researchers lack guidance, regarding how QLQ-CIPN20 results relate to the traditional CTCAE during the serial assessment of patients undergoing chemotherapy.

Methods

Two large CIPN clinical trial datasets (538 patients) pairing QLQ-CIPN20 and CTCAE outcomes were analyzed using a multivariable linear mixed model with QLQ-CIPN20 score as the outcome variable, CTCAE grade as the main effect, and patient as random effect (accounting for internal correlation of serial measures).

Results

The association between QLQ-CIPN20 scores and CTCAE grades was strong (p < 0.0001), whereby patients with higher CTCAE grade had worse QLQ-CIPN20 scores. Some variation of QLQ-CIPN20 scores was observed based on drug, treatment, and cycle. While there was a marked difference in the mean QLQ-CIPN20 scores between CTCAE grades, the ranges of QLQ-CIPN20 scores within each CTCAE grade were large, leading to large overlap in CIPN20 scores across CTCAE grades.

Conclusions

A strong positive association of QLQ-CIPN20 scores and CTCAE grade provides evidence of convergent validity as well as practical guidance, as to how to quantitatively interpret QLQ-CIPN20 scores at the study level in terms of the traditional CTCAE. The present results also highlight an important clinical caveat, specifically, that conversion of a specific QLQ-CIPN20 score to a specific CTCAE score may not be reliable at the level of an individual patient.

Keywords

Peripheral neuropathy CTCAE EORTC QLQ-CIPN20 Patient-reported outcome Physician-reported outcome 

Notes

Acknowledgments

The authors wish to thank Dr. Cynthia Lynch from the Mayo Clinic for the accrual contribution to NCCTG N08CA and Dr. Nassim Nabbout from the Wichita NCI Community Oncology Research Program for the accrual contribution to NCCTG N08CB.

Compliance with ethical standards

Support

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under the Award Number UG1CA189823 (to the Alliance for Clinical Trials in Oncology NCORP Grant) and U10CA180790 and by the National Institute of Nursing Research (NINR) of the National Institutes of Health (NIH) under Award Number R01NR015259 (to A.S.B.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest

The authors declare that they have no conflicts of interest.

Supplementary material

520_2017_3780_MOESM1_ESM.docx (16 kb)
Table S1 (DOCX 16 kb)
520_2017_3780_MOESM2_ESM.docx (16 kb)
Table S2 (DOCX 15 kb)

References

  1. 1.
    Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL (2011) The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Supportive Care Cancer 19:1769–1777CrossRefGoogle Scholar
  2. 2.
    Hershman DL, Unger JM, Crew KD, Minasian LM, Awad D, Moinpour CM, Hansen L, Lew DL, Greenlee H, Fehrenbacher L, Wade JL III, Wong SF, Hortobagyi GN, Meyskens FL, Albain KS (2013) Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy. J Clin Oncol 31:2627–2633CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Zimmerman C, Atherton PJ, Pachman D, Seisler D, Wagner-Johnston N, Dakhil S, Lafky JM, Qin R, Grothey A, Loprinzi C (2015) MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. Support Care Cancer, 1–8Google Scholar
  4. 4.
    Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer 22:2261–2269CrossRefPubMedGoogle Scholar
  5. 5.
    Hershman DL, Lacchetti C, Dworkin RH, Smith EML, Bleeker J, Cavaletti G, Chauhan C, Gavin P, Lavino A, Lustberg MB, Paice J, Schneider B, Smith ML, Smith T, Terstriep S, Wagner-Johnston N, Bak K, Loprinzi C (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, JCO – 2013Google Scholar
  6. 6.
    Postma TJ, Heimans JJ, Muller MJ, Ossenkoppele GJ, Vermorken JB, Aaronson NK (1998) Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9:739–744CrossRefPubMedGoogle Scholar
  7. 7.
    Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clinical Pharmacology & Therapeutics 90:377–387CrossRefGoogle Scholar
  8. 8.
    Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Frigeni B, Alberti P et al (2012) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 0:1–9Google Scholar
  9. 9.
    Gilchrist L (2012) Chemotherapy-induced peripheral neuropathy in pediatric cancer patients. Semin Pediatr Neurol 19:9–17CrossRefPubMedGoogle Scholar
  10. 10.
    Visovsky C (2013) Challenges in the conduct of research: chemotherapy-induced peripheral neuropathy. J Adv Pract Oncol 4:369–371PubMedPubMedCentralGoogle Scholar
  11. 11.
    Liu H, Tan AD, Qin R, Sargent DJ, Grothey A, Buckner JC, Schaefer PL, Sloan JA (2015) Comparing and validating simple measures of patient-reported peripheral neuropathy for oncology clinical trials: NCCTG N0897 (Alliance) a pooled analysis of 2440 patients. SOJ Anesthesiol Pain Manag 2:1–9Google Scholar
  12. 12.
    Stephens RJ, Hopwood P, Girling DJ, Machin D (1997) Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Qual Life Res 6:225–236CrossRefPubMedGoogle Scholar
  13. 13.
    Shimozuma K, Ohashi Y, Takeuchi A, Arnishi T, Morita S, Kuroi K et al (2009) Validation of the Patient Neurotoxicity Questionnaire (PNQ) during taxane chemotherapy in a phase III randomized trial of breast cancer: N-SAC BC 02. Support Care Cancer 17:1483–1491CrossRefPubMedGoogle Scholar
  14. 14.
    Smith EML, Barton DL, Qin R, Steen PD, Aaronson NK, Loprinzi CL (2013) Assessing patient-reported peripheral neuropathy: the reliability and validity of the European Organization for Research and Treatment of Cancer QLQ-CIPN20 Questionnaire. Qual Life Res 22:2787–2799CrossRefGoogle Scholar
  15. 15.
    Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY, Hoang-Xuan K, Lantéri-Minet M, Grant R, Huddart R, Moynihan C (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139CrossRefPubMedGoogle Scholar
  16. 16.
    Pace A, Nisticó C, Cuppone F, Bria E, Galié E, Graziano G, Natoli G, Sperduti I, Jandolo B, Calabretta F, Tomao S, Terzoli E (2007) Peripheral neurotoxicity of weekly paclitaxel chemotherapy: a schedule or a dose issue? Clinical Breast Cancer 7:550–554CrossRefPubMedGoogle Scholar
  17. 17.
    Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D (2007) Health-related quality of life during and after Intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a gynecologic oncology group study. J Clin Oncol 25:437–443CrossRefPubMedGoogle Scholar
  18. 18.
    Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, LeLindqwister NA, Doori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472–1478CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, Ruddy KJ, Loprinzi CL (2015) Can pregabalin prevent paclitaxel-associated neuropathy?—An ACCRU pilot trial. Support Care Cancer, 1–7Google Scholar
  20. 20.
    Barton DL, Wos EJ, Qin R, Mattar BI, Green NB, Lanier S et al (2011) A double-blind, placebo-controlled trial of a topical treatment for chemotherapy-induced peripheral neuropathy: NCCTG trial N06CA. Support Care Cancer 19:833–841CrossRefPubMedGoogle Scholar
  21. 21.
    Loprinzi CL, Qin R, Dakhil SR, Fehrenbacher L, Flynn DA, Atherton P, Seisler D, Qamar R, Lewis GC, Grothey A (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance). J Clin Oncol 32:997–1005CrossRefPubMedGoogle Scholar
  22. 22.
    Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber CH, Watanaboonyakhet P, Weiss M, Adams PT, Dockter TJ, Loprinzi CL, for the Alliance for Clinical Trials in Oncology (2014) North Central Cancer Treatment Group/Alliance trial N08CA—the use of glutathione for prevention of paclitaxel/carboplatin-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled study. Cancer 120:1890–1897CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Alberti P, Rossi E, Cornblath DR, Merkies ISJ, Postma TJ, Frigeni B, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Cavaletti G, the CI-PeriNomS Group (2014) Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. Ann Oncol 25:257–264CrossRefPubMedGoogle Scholar
  24. 24.
    Dueck AC, Mendoza TR, Mitchell SA et al (2015) Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 1(8):1051–1059. doi: 10.1001/jamaoncol.2015.2639 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Jennifer Le-Rademacher
    • 1
    • 2
  • Rahul Kanwar
    • 3
  • Drew Seisler
    • 1
  • Deirdre R. Pachman
    • 2
    • 3
  • Rui Qin
    • 1
    • 4
  • Alexej Abyzov
    • 1
  • Kathryn J. Ruddy
    • 2
    • 3
  • Michaela S. Banck
    • 2
    • 3
  • Ellen M. Lavoie Smith
    • 5
  • Susan G. Dorsey
    • 6
  • Neil K. Aaronson
    • 7
  • Jeff Sloan
    • 1
    • 2
  • Charles L. Loprinzi
    • 2
    • 3
  • Andreas S. Beutler
    • 2
    • 3
  1. 1.Alliance Statistics and Data CenterMayo ClinicRochesterUSA
  2. 2.Mayo Clinic Cancer CenterMayo ClinicRochesterUSA
  3. 3.Department of OncologyMayo ClinicRochesterUSA
  4. 4.Regeneron PharmaceuticalsBasking RidgeUSA
  5. 5.Department of Health Behavior and Biological Sciences, School of NursingUniversity of MichiganAnn ArborUSA
  6. 6.Pain and Translational Symptom Science Department, School of NursingUniversity of MarylandBaltimoreUSA
  7. 7.Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, Department of Clinical PsychologyUniversity of AmsterdamAmsterdamNetherlands

Personalised recommendations